• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.48% Nasdaq Up0.29%

    Tesaro, Inc. (TSRO)

    -NasdaqGS
    46.30 Up 2.49(5.68%) May 31, 4:00PM EDT
    |After Hours : 46.30 0.00 (0.00%) May 31, 4:36PM EDT
    ProfileGet Profile for:
    Tesaro, Inc.
    1000 Winter Street
    Suite 3300
    Waltham, MA 02451
    United States - Map
    Phone: 339-970-0900
    Website: http://www.tesarobio.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:286

    Business Summary 

    TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor to treat ovarian or breast cancers; and TSR-011, an anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA and OPDIVO, an anti-PD-1 antibody products, for the treatment of certain non-small cell lung cancers; and develops immunotherapy antibody product candidates targeting PD-1 (TSR-042) and TIM-3 (TSR-022), as well as LAG-3 and bi-specific antibody product candidates targeting PD-1/TIM-3, PD-1/LAG-3, and an additional bi-specific combination to treat various tumors. It has strategic research collaboration with Myriad Genetics, Inc. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Tesaro, Inc.

    Corporate Governance 
    Tesaro, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 3; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Leon O. Moulder Jr., M.B.A., 59
    Co-Founder, Chief Exec. Officer and Director
    915.00K0.00
    Dr. Mary Lynne Hedley Ph.D., 53
    Co-Founder, Pres, Chief Operating Officer and Director
    849.00K0.00
    Mr. Timothy R. Pearson , 48
    Chief Financial Officer and Exec. VP
    565.00K0.00
    Mr. Jeffrey H. Hanke Ph.D., 59
    Chief Scientific Officer and Exec. VP of R&D
    340.00K0.00
    Mr. Grant C. Bogle , 58
    Chief Commercial Officer and Sr. VP
    381.00K0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders